ChiCTR2600126583 版本V1.0 版本创建时间2026/06/11 16:27:45 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2600126583 

最近更新日期:

Date of Last Refreshed on:

2026-06-11 16:27:26 

注册时间:

Date of Registration:

2026-06-11 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

下肢骨折患者中基于股静脉及小腿深静脉阴性结果排除腘静脉血栓的诊断准确性研究

Public title:

Diagnostic accuracy of excluding popliteal vein thrombosis based on negative findings in the femoral vein and calf deep veins in patients with lower extremity fractures

注册题目简写:

English Acronym:

研究课题的正式科学名称:

下肢骨折患者中基于股静脉及小腿深静脉阴性结果排除腘静脉血栓的诊断准确性研究

Scientific title:

Diagnostic accuracy of excluding popliteal vein thrombosis based on negative findings in the femoral vein and calf deep veins in patients with lower extremity fractures

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

徐琦 

研究负责人:

徐琦 

Applicant:

Xu Qi 

Study leader:

Xu Qi 

申请注册联系人电话:

Applicant telephone:

+86 27 6883 1500

研究负责人电话:

Study leader's
telephone:

+86 27 6883 1500

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

21514668@qq.com

研究负责人电子邮件:

Study leader's E-mail:

21514668@qq.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

湖北省武汉市硚口区汉正街473号

研究负责人通讯地址:

湖北省武汉市硚口区汉正街473号

Applicant address:

No. 473, Hanzheng Street, Qiaokou District, Wuhan, Hubei Province

Study leader's address:

No. 473, Hanzheng Street, Qiaokou District, Wuhan, Hubei Province

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

武汉市第四医院

Applicant's institution:

Wuhan Fourth Hospital

研究负责人所在单位:

武汉市第四医院

Affiliation of the Leader:

Wuhan Fourth Hospital

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

伦审字(KY2026-056-01)号

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

武汉市第四医院伦理委员会

Name of the ethic committee:

Ethics Committee of Wuhan Fourth Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2026-05-15 00:00:00

伦理委员会联系人:

郭朝晖

Contact Name of the ethic committee:

Guo ChaoHui

伦理委员会联系地址:

湖北省武汉市硚口区汉正街473号

Contact Address of the ethic committee:

No. 473, Hanzheng Street, Qiaokou District, Wuhan, Hubei Province

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 27 68834993

伦理委员会联系人邮箱:

Contact email of the ethic committee:

573187677@qq.com

研究实施负责(组长)单位:

武汉市第四医院

Primary sponsor:

Wuhan Fourth Hospital

研究实施负责(组长)单位地址:

湖北省武汉市硚口区汉正街473号

Primary sponsor's address:

No. 473, Hanzheng Street, Qiaokou District, Wuhan, Hubei Province

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

湖北省

市(区县):

Country:

China

Province:

Hubei

City:

单位(医院):

武汉市第四医院

具体地址:

湖北省武汉市硚口区汉正街473号

Institution
hospital:

Wuhan Fourth Hospital

Address:

No. 473, Hanzheng Street, Qiaokou District, Wuhan, Hubei Province

经费或物资来源:

自选课题(自筹)

Source(s) of funding:

Self-funded (self-raised funds)

研究疾病:

下肢骨折合并深静脉血栓(腘静脉血栓)  

Target disease:

Deep vein thrombosis (popliteal vein) associated with lower extremity fractures

研究疾病代码:

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

连续入组 

Study design:

Sequential 

研究目的:

主要目的:评估下肢骨折患者中,股静脉及所有小腿深静脉(含肌间静脉)阴性时排除腘静脉血栓的诊断价值(以腘静脉血栓检出率和阴性预测值表示)。 次要目的:评估狭义小腿静脉定义下的诊断性能;分析30天内新发腘静脉血栓发生率;探讨骨折部位及术前/术后状态的影响;评估超声报告判读一致性。  

Objectives of Study:

Primary Objective: To assess the diagnostic value (detection rate and NPV) of excluding popliteal vein thrombosis based on negative findings in the femoral vein and all calf deep veins (including intermuscular veins) in patients with lower extremity fractures.Secondary Objectives: (1) To evaluate diagnostic performance using a narrow definition of calf DVT; (2) To determine 30-day incidence of new popliteal DVT; (3) To analyze effects of fracture site and preoperative/postoperative status; (4) To assess inter-reader reliability of ultrasound reports.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1.年龄≥18岁;
2.因下肢骨折(股骨、胫腓骨、踝关节/足部)住院;
3.住院期间完成了包含股静脉、腘静脉及小腿深静脉(含肌间静脉)的完整下肢深静脉超声检查;
4.超声检查在受伤后30天内完成。

Inclusion criteria

1.Age >= 18 years; 2.Hospitalized for lower extremity fractures (femur, tibiofibula, ankle/foot); 3.Underwent complete lower extremity deep vein ultrasound examination including femoral vein, popliteal vein, and calf deep veins (including intermuscular veins) during hospitalization; 4.Ultrasound examination performed within 30 days after injury.

排除标准:

1.既往有深静脉血栓(DVT)或肺栓塞(PE)病史;
2.检查时正在接受抗凝治疗(如华法林、低分子肝素、新型口服抗凝药等);
3.合并活动期恶性肿瘤;
4.有下肢静脉手术史或下肢静脉曲张史;
5.超声检查记录不完整,无法明确各血管段结果。

Exclusion criteria:

1.Prior history of deep vein thrombosis (DVT) or pulmonary embolism (PE);
2.Receiving anticoagulant therapy (e.g., warfarin, low molecular weight heparin, direct oral anticoagulants) at the time of ultrasound examination;
3.Active malignant tumor;
4.History of lower extremity venous surgery or varicose veins;
5.Incomplete ultrasound records that preclude definitive interpretation of each vascular segment.

研究实施时间:

Study execute time:

From 2026-05-01 00:00:00 To 2026-12-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2026-06-30 00:00:00 To 2026-12-21 00:00:00

干预措施:

Interventions:

组别:

阳性组

样本量:

400

Group:

Positive group

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

组别:

阴性组

样本量:

800

Group:

Negative group

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

湖北省 

市(区县):

 

Country:

China

Province:

Hubei

City:

单位(医院):

武汉市第四医院 

单位级别:

三级甲等 

Institution
hospital:

Wuhan Fourth Hospital

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

腘静脉血栓检出率 (阴性组中)

指标类型:

主要指标

Outcome:

Detection rate of popliteal vein thrombosis (in negative group)

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

阴性组中首次超声后 30 天内新发腘静脉血栓(按是否伴有其他新发血栓分为孤立性/ 非孤立性)的发生率

指标类型:

次要指标

Outcome:

The incidence of new popliteal vein thrombosis within 30 days after the first ultrasound in the negative group (classified as isolated or non-isolated depending on the presence of other new thromboses)

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

阴性组中 30 天内经证实 PE 的发生率

指标类型:

次要指标

Outcome:

The incidence of confirmed PE within 30 days in the negative group

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

盲法判读与原始报告的一致性(Kappa 值)

指标类型:

次要指标

Outcome:

Agreement between blinded reading and original report (Kappa value)

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

None

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

None

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

Blinding:

None

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

None

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

数据来源于我院电子病历系统(HIS)及超声影像归档系统(PACS)。由两名研究人员独立提取数据并交叉核对。数据录入采用Excel(版本16.0)建立数据库,采用双录入法校验一致性。最终数据分析时采用SPSS 26.0和R 4.2。数据存储于医院内部加密服务器,仅限课题组核心成员访问。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Data will be extracted from the Hospital Information System (HIS) and PACS. Two researchers will independently extract and cross-check the data. A database will be built using Excel (version 16.0) with double data entry. Final analysis will use SPSS 26.0 and R 4.2. Data will be stored on an encrypted hospital server accessible only to core team members.

数据与安全监察委员会:

Data and Safety Monitoring Committee:

无/No

注册人:

Name of Registration:

 2026-06-11 16:27:26